HELP — CYBIN INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1833141 ·
Last close
$13.02
Market Cap
$951.24M
52W High
$13.24
52W Low
$3.76
ADV30
1,916,970
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -47,859,000 | -46,995,000 | 251,166,000 | 157,258,000 | 19,377,000 |
| Dec 2025 | 0 | — | -41,210,000 | -42,668,000 | 290,112,000 | 195,128,000 | 16,178,000 |
| Sep 2025 | 0 | — | -28,894,000 | -33,722,000 | 181,246,000 | 83,752,000 | 42,250,000 |
| Jun 2025 | 0 | — | -24,624,000 | -24,613,000 | 210,813,000 | 118,692,000 | 59,053,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-133,271,000
Investing CF
$-1,363,000
Financing CF
$198,239,000
CapEx
$-1,373,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.87
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-389,535,000
Inventory
—
Receivables
$5,028,000
ST Investments
—
EBIT TTM
$-142,587,000
Pretax Income TTM
$-147,998,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -142,587,000 | -147,998,000 | 251,166,000 | 19,377,000 | — | -133,271,000 |
| Mar 2025 | 0 | -103,125,000 | -81,607,000 | 179,897,000 | 14,900,000 | — | -72,328,000 |
| Mar 2024 | 0 | -78,836,000 | -78,080,000 | 302,023,000 | 10,096,000 | — | -68,908,000 |
| Mar 2023 | 0 | -51,518,000 | -47,490,000 | 53,897,000 | 5,663,000 | — | -47,431,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.84
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $13.02 · call volume: 2,128 · put volume: 4
Expected Move to 2026-12-18:
±$9.99
(76.73%) —
implied range
$3.03 –
$23.01
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | $953.12M | $15.23 | — |
| ANNX | Annexon, Inc. | $959.27M | $5.06 | — |
| CLYM | Climb Bio, Inc. | $941.95M | $16.40 | — |
| ARDX | ARDELYX, INC. | $965.62M | $3.74 | — |
| IMMX | Immix Biopharma, Inc. | $968.90M | $13.61 | — |
News headlines (Yahoo Finance, 1h cache)
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?
2026-06-26 22:09 · Yahoo
Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions
2026-08-22 10:09 · Yahoo
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now
2026-08-21 05:16 · Yahoo
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
2026-08-18 11:30 · Yahoo
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
2026-08-14 11:28 · Yahoo
Cybin (HELP) Names New CEO, Is The Stock Still Cheap?
2026-08-08 18:10 · Yahoo
Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?
2026-08-06 14:18 · Yahoo
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
2026-08-03 11:40 · Yahoo
Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions
2026-07-25 15:13 · Yahoo
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
2026-07-22 17:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.